


Listing of the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Previously presented) An imidazotriazinone compound represented by the following formula (IA):



wherein

A is N or CR⁴;

B is N or CH;

R¹ is substituted or unsubstituted cycloalkyl group or tert-butyl group;

R² is a hydrogen atom or C₁-C₆ alkyl group;

R³ is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C₁-C₆ alkyl group; substituted or unsubstituted C₂-C₆ alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: -NR⁵R⁶, -C(O)R⁷, -SO₂R⁷, -OR⁸, -NR⁸COR⁷, -NR⁸SO₂R⁷;

R⁴ is a hydrogen atom or C₁-C₃ alkoxy group which is unsubstituted or substituted by one or more fluorine atom(s);

R⁵ and R⁶ are, same or different from each other, a hydrogen atom; substituted or unsubstituted C₁-C₆ alkyl group; substituted or unsubstituted acyl group; or substituted or unsubstituted heterocycloalkyl group;

R⁷ is a hydrogen atom; substituted or unsubstituted C₁-C₆ alkyl group; substituted or unsubstituted heterocycloalkyl group; OH; -OR⁸ or -NR⁵R⁶;

R⁸ is a hydrogen atom, substituted or unsubstituted C₁-C₆ alkyl group; or substituted or unsubstituted heterocycloalkyl group; or pharmaceutically acceptable salts thereof.

2. (Canceled)

3. (Canceled)
4. (Original) The compound according to claim 1, in which R¹ is substituted or unsubstituted C₃-C₈ cycloalkyl group.
5. (Previously Presented) The compound according to claim 4, in which R¹ is cyclopentyl, cyclohexyl or cycloheptyl.
6. (Previously Presented) The compound according to claim 1, in which A is CR⁴ wherein R⁴ is methoxy or ethoxy group.
7. (Previously Presented) The compound according to claim 1, in which B is CH.
8. (Previously Presented) The compound according to claim 1, in which R² is methyl group.
9. (Previously Presented) The compound according to claim 1, in which R³ is a hydrogen atom; a halogen atom; saturated or unsaturated heterocycloalkyl group; an -NR⁵R⁶, -C(O)R⁷, or -SO₂R⁷ group, wherein R⁷ is OH, -OR⁸, -NR⁵R⁶ or a substituted or unsubstituted heterocycloalkyl group.
10. (Currently amended) A pharmaceutical composition comprising a compound according to claim 1, or pharmaceutically acceptable salts thereof as an active ingredient.
11. (Canceled)
12. (New) The compound of claim 1, wherein the compound is 6-cyclohexyl-2-(2-methoxyphenyl)-8-methylimidazo-[1,5-a][1,3,5]-triazin-4(3H)-one; or 6-cyclohexyl-2-(4-bromo-2-methoxyphenyl)-8-methylimidazo-[1,5-a][1,3,5]triazin-4(3H)-one.
13. (New) The compound of claim 1, wherein the compound is 6-cyclohexyl-2-[2-methoxy-4-(1-piperazinyl)phenyl]-8-methylimidazo-[1,5-a][1,3,5]triazin-4(3H)-one; or 6-cyclohexyl-

- 2-[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]-8-methylimidazo-[1,5-a][1,3,5]triazin-4(3H)-one.
14. (New) The compound of claim 1, wherein the compound is 2-[4-(4-amino-1-piperidinyl)-2-methoxyphenyl]-6-cyclohexyl-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; 6-cyclohexyl-2-{2-methoxy-4-[4-(methylamino)-1-piperidinyl]phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; 6-cyclohexyl-2-{4-[4-(dimethylamino)-1-piperidinyl]-2-methoxy-phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; or 6-cyclohexyl-2-[4-(4-hydroxy-1-piperidinyl)-2-methoxyphenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.
15. (New) The compound of claim 1, wherein the compound is 6-cyclohexyl-2-[4-(1,4-diazepan-1-yl)-2-methoxyphenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; or 6-cyclohexyl-2-[2-methoxy-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.
16. (New) The compound of claim 1, wherein the compound is 6-cyclohexyl-2-{4-[(4-hydroxy-1-piperidinyl)sulfonyl]-2-methoxyphenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; 6-cyclohexyl-2-[2-methoxy-4-(1-piperazinylsulfonyl)phenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; 6-cyclohexyl-2-{2-methoxy-4-[(4-methyl-1-piperazinyl)sulfonyl]-phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; 6-cyclohexyl-2-[4-(1,4-diazepan-1-ylsulfonyl)-2-methoxyphenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; or 6-cyclohexyl-2-{2-methoxy-4-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]-phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.
17. (New) The compound of claim 16, wherein the compound is 6-cyclohexyl-2-{4-[(4-hydroxy-1-piperidinyl)sulfonyl]-2-methoxyphenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.
18. (New) The compound of claim 16, wherein the compound is 6-cyclohexyl-2-[2-methoxy-4-(1-piperazinylsulfonyl)phenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; or 6-cyclohexyl-2-{2-methoxy-4-[(4-methyl-1-piperazinyl)sulfonyl]-phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.

19. (New) The compound of claim 16, wherein the compound is 6-cyclohexyl-2-[4-(1,4-diazepan-1-ylsulfonyl)-2-methoxyphenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; or 6-cyclohexyl-2-{2-methoxy-4-[(4-methyl-1,4-diazepam-1-yl)sulfonyl]-phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.
20. (New) The compound of claim 1, wherein the compound is 6-cyclohexyl-2-(2-ethoxyphenyl)-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.
21. (New) The compound of claim 1, wherein the compound is 6-cyclohexyl-2-[2-ethoxy-4-(1-piperazinyl)phenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; or 6-cyclohexyl-2-[2-ethoxy-4-(4-methyl-1-piperazinyl)phenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.
22. (New) The compound of claim 1, wherein the compound is 2-[4-(4-amino-1-piperidiny)-2-ethoxyphenyl]-6-cyclohexyl-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; 6-cyclohexyl-2-{2-ethoxy[4-(methylamino)-1-piperidiny]phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; 6-cyclohexyl-2-{4-[4-(dimethylamino)-1-piperidiny]-2-ethoxy-phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; or 6-cyclohexyl-2-[4-(4-hydroxy-1-piperidiny)-2-ethoxyphenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.
23. (New) The compound of claim 1, wherein the compound is 6-cyclohexyl-2-[4-(1,4-diazepan-1-yl)-2-ethoxyphenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; or 6-cyclohexyl-2-[2-ethoxy-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.
24. (New) The compound of claim 1, wherein the compound is 6-cyclohexyl-2-{4-[4-(4-hydroxy-1-piperidiny)sulfonyl]-2-ethoxy-phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; 6-cyclohexyl-2-[2-ethoxy-4-(1-piperazinylsulfonyl)phenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; 6-cyclohexyl-2-{2-ethoxy-4-[(4-methyl-1-piperazinyl)sulfonyl]-phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; 6-cyclohexyl-2-[4-(1,4-diazepan-1-ylsulfonyl)-2-ethoxyphenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-

4(3H)-one; or 6-cyclohexyl-2-{2-ethoxy-4-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]-phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.

25. (New) The compound of claim 24, wherein the compound is 6-cyclohexyl-2-{4-[(4-hydroxy-1-piperidiny)sulfonyl]-2-ethoxy-phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.
26. (New) The compound of claim 24, wherein the compound is 6-cyclohexyl-2-[2-ethoxy-4-(1-piperazinylsulfonyl)phenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; or 6-cyclohexyl-2-{2-ethoxy-4-[(4-methyl-1-piperazinyl)sulfonyl]-phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.
27. (New) The compound of claim 24, wherein the compound is 6-cyclohexyl-2-[4-(1,4-diazepan-1-ylsulfonyl)-2-ethoxyphenyl]-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one; or 6-cyclohexyl-2-{2-ethoxy-4-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]-phenyl}-8-methylimidazo[1,5-a][1,3,5]triazin-4(3H)-one.